BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20280326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20281029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250301T080000
DTEND;TZID=Europe/Vienna:20270330T170000
DTSTAMP:20260421T184442
CREATED:20251117T100100Z
LAST-MODIFIED:20251117T102105Z
UID:3297-1740816000-1806426000@esmit.eanm.org
SUMMARY:Fundamentals of Research in Imaging and Theranostics Part 2
DESCRIPTION:UEMS EACCME has granted the accreditation of 4.5 CME credits for this event. \n\n\n\n \n\n\n\n \n\n\n\nThis online course is part of a longer line of research methodology which is aimed at providing interested participants with information about the preclinical development and clinical translation\, as well as the design\, conductance and reporting of clinical research trials\, with a specific emphasis on radiopharmaceuticals for both diagnostic and therapeutic applications. \n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n \n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\nFor phase I/II clinical studies with radiopharmaceuticals to understand:    \n\n\n\n\nThe principles of technical realisation of the study including assessment of safety of investigational medicinal product \n\n\n\nThe statistical considerations\, including the estimation of number of subjects to be enrolled  \n\n\n\nThe regulatory requirements for performing clinical studies with radiopharmaceutical with special focus on diagnostic radiopharmaceuticals and to summarise the particularities of these studies \n\n\n\nThe ethical and medical considerations in common and vulnerable populations \n\n\n\nThe principles of preparing the clinical study protocol  \n\n\n\nThe objectives\, endpoints and outcome measures  \n\n\n\nThe principles of patient selection\, inclusion and non-inclusion criteria \n\n\n\nThe principles of establishment of the standard of truth\, the role of the comparator\, superiority/non-inferiority/equivalence(?) studies) & practical examples\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n \n\n\n\n\nPersonnel involved in designing and/or performing phase I/II clinical research with diagnostic radiopharmaceuticals (e.g. nuclear medicine physicians\, pharmacists\, physicists\, nurses\, technologist\, administrative staff). \n\n\n\nPersonnel involved in assessment of the ethical\, medical and methodologic aspects of phase I/II research protocols with diagnostic radiopharmaceuticals. \n\n\n\nAll professionals interested in phase I/II clinical research with diagnostic radiopharmaceuticals \n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nChiara GranaSpeaker \n\n\n\n\n\nBart de KeizerSpeaker \n\n\n\n\n\nCaroline StokkeSpeaker \n\n\n\n\n\nJean-Noel TalbotSpeaker \n\n\n\n\n\n\n\nLuisa Roldao PereiraSpeaker \n\n\n\n\n\nJohn Andrei IagaruSpeaker \n\n\n\n\n\nSona BalogovaSpeaker
URL:https://esmit.eanm.org/event/fundamentals-of-research-part-2/
CATEGORIES:Online Course,Research Methods,Self-paced Online Course,Theranostics
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250425T000000
DTEND;TZID=Europe/Vienna:20260425T235959
DTSTAMP:20260421T184442
CREATED:20250225T141140Z
LAST-MODIFIED:20250605T144111Z
UID:2257-1745539200-1777161599@esmit.eanm.org
SUMMARY:Highlights of Focus Meeting 6: Shaping the Future of Breast Cancer Care with Molecular Imaging
DESCRIPTION:Breast cancer remains the most frequently diagnosed cancer and the leading cause of cancer-related death in women worldwide. Despite significant advancements in imaging and treatment\, clinical practice remains heterogeneous across institutions and disciplines. Molecular imaging has a pivotal role in breast cancer care\, from diagnosis to recurrence assessment. To address these discrepancies and define the future direction of imaging in breast cancer\, the European Association of Nuclear Medicine (EANM) devoted its 6th Focus Meeting to this topic\, under the following motto “Shaping the Future of Breast Cancer Care with Molecular Imaging”. \n\n\n\n \n\n\n\nThe aims of this project were: \n\n\n\n\nTo define the role of imaging in breast cancer\, particularly the utility of nuclear medicine techniques in different clinical settings (including initial systemic staging\, assessment of response to therapy\, and detection of recurrence). \n\n\n\nTo reach a multidisciplinary consensus on the current state of the art in nuclear medicine imaging in breast cancer.\n\n\n\nTo generate expert recommendations on how best to guide professionals in their clinical decisions\, beyond the existing guidelines. \n\n\n\nTo identify knowledge gaps and topics with lack of scientific evidence for potential future studies.\n\n\n\n\n \n\n\n\n \n\n\n\nThe recordings in this course are sponsored by Novartis. \n\n\n\n\n\n\n\n\n\nRegister nowEnrol in the online course now for free! Register now\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\n\nIsabel T. RubioSpeaker \n\n\n\n\n\nFrederique Penault LlorcaSpeaker \n\n\n\n\n\nThiemo van NijnattenSpeaker \n\n\n\n\n\nElizabeth DibbleSpeaker \n\n\n\n\n\nTessa BuckleSpeaker \n\n\n\n\n\nKatja Pinker DomenigSpeaker \n\n\n\n\n\n\n\n\n\nSofia Carrilho-VazSpeaker \n\n\n\n\n\nMartina Bašić-KoretićSpeaker \n\n\n\n\n\nDavid GroheuxSpeaker \n\n\n\n\n\nGary UlanerSpeaker \n\n\n\n\n\nGeraldine GebhartSpeaker \n\n\n\n\n\nWolfgang WeberSpeaker \n\n\n\n\n\n\n\n\n\nValeria RomeoSpeaker \n\n\n\n\n\nAlessandra GennariSpeaker \n\n\n\n\n\nKarolien GoffinSpeaker \n\n\n\n\n\nNadia HarbeckSpeaker \n\n\n\n\n\nPascal BaltzerSpeaker \n\n\n\n\n\nMichel van KruchtenSpeaker \n\n\n\n\n\n\n\n\n\nGary Cook Speaker \n\n\n\n\n\nPaola Anna ErbaSpeaker \n\n\n\n\n\nJoana M RibeiroSpeaker \n\n\n\n\n\nCarolien SchröderSpeaker \n\n\n\n\n\nRitse MannSpeaker \n\n\n\n\n\nPhilipp BackhausSpeaker \n\n\n\n\n\n\n\n\n\nMalene Gubbe Hildebrand Speaker \n\n\n\n\n\nFatima CardosoSpeaker \n\n\n\n\n\nAntoinette AttardSpeaker \n\n\n\n\n\nFrancesco SchnettiniSpeaker \n\n\n\n\n\nSofia RiveraSpeaker \n\n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/highlights-of-focus-meeting-6-shaping-the-future-of-breast-cancer-care-with-molecular-imaging/
LOCATION:Online
CATEGORIES:Clinical Nuclear Medicine,Self-paced Online Course
ORGANIZER;CN="ESMIT":MAILTO:esmit@eanm.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250601T000000
DTEND;TZID=Europe/Vienna:20250601T235959
DTSTAMP:20260421T184442
CREATED:20240215T124600Z
LAST-MODIFIED:20251016T123616Z
UID:1358-1748736000-1748822399@esmit.eanm.org
SUMMARY:Parathyroid Imaging (Self-paced)
DESCRIPTION:UEMS EACCME has granted the accreditation of 2.5 CME credits for this event. \n\n\n\nThis self-paced online course will offer a comprehensive exploration of the anatomy\, physiology\, and diagnostic tools related to parathyroid glands disorders. The course will cover a range of topics\, including the regulation of parathyroid hormone (PTH) secretion and his mechanisms of action\, etiology\, clinical manifestations\, and notably the diagnostic approaches ( laboratory and imaging)\, and treatment modalities especially concerning hyperparathyroidism. \n\n\n\n\n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\nLearning Objectives\n\n\n\n \n\n\n\nAttendees will gain insights into structure and function of the parathyroid glands\, earning about etiology\, clinical manifestations\, diagnostic approaches focused on nuclear medicine and radiological techniques and treatment modalities of hyperparathyroidism. Through lectures\, and case studies\, participants will acquire the knowledge and skills necessary to diagnose and manage parathyroid disorders. \n\n\n\n\n\n\n\nTarget audience\n\n\n\n \n\n\n\nThis course is designed for Nuclear Medicine Physicians\, Endocrinologists and Radiologists. \n\n\n\n\n\n\n\nProgrammeClick to see the Preliminary Programme. Please note\, that it may be subject to change at any time. Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\nLuca GiovanellaZurich\, Switzerland \n\n\n\nMurat TuncelAnkara\, Türkiye \n\n\n\nMichael KreisslMagdeburg\, Germany \n\n\n\nPetra PetranovicZagreb\, Croatia \n\n\n\n\nRegistration Details\n\n\n\nRegistration Fee\n\nCourse Fee              Free \n\n\n\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired course under ‘Online Courses’  \n\n\n\nEnjoy!Once enrolled\, you get full access to the course contents on the ESMIT eLearning platform \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/parathyroid-imaging/
LOCATION:Online
CATEGORIES:Clinical Nuclear Medicine,Self-paced Online Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250601T000000
DTEND;TZID=Europe/Vienna:20250601T235959
DTSTAMP:20260421T184442
CREATED:20251030T142906Z
LAST-MODIFIED:20251031T095911Z
UID:1346-1748736000-1748822399@esmit.eanm.org
SUMMARY:Bringing Alpha Therapies into Clinical Practice
DESCRIPTION:UEMS EACCME has granted the accreditation of 3 CME credits for this event. \n\n\n\n \n\n\n\n \n\n\n\nThis online course offers a comprehensive introduction to alpha therapy in nuclear medicine\, with a focus on the fundamental principles and clinical applications of Alpha-Therapy in the fields of Radiopharmaceutical Sciences\, Oncology and Dosimetry. Alpha Therapy is a cutting-edge cancer treatment using alpha radiation. It represents a form of targeted radionuclide therapy that uses alpha-emitting radioisotopes to deliver lethal doses of radiation directly to cancer cells while sparing healthy tissues. It is highly efficient and lately increasingly explored for scientific purposes in the oncologic domain . With this course we aim at bringing Alpha Therapies into clinical practice through various\, relevant presentations. A panel of experts and EANM members will update you on the type of alpha-emitting radioisotopes available\, describing all important steps required for production and radiopharmaceutical development. The advantages\, but also the challenges related to the use of Alpha therapy will amply be discussed and supported by clinical examples. You will be initiated in the existing and ongoing therapeutic trials\, with the best yet to come. Dosimetry will play a pivotal role in this course\, underlying its role in clinical practice. Finally\, The Alphamet project will be presented\, allowing you to get updated with the latest insights from Theranostics. \n\n\n\nRPH \n\n\n\nTargeted Alpha Therapy (TAT) represents a cutting-edge advancement in cancer treatment\, harnessing the potent\, cell-killing power of alpha particles to precisely destroy malignant cells while minimizing damage to surrounding healthy tissue. This part of the course course explores the transformative potential of TAT\, highlighting its exceptional potency\, unique ability to overcome radio-resistance\, and its role in modern theranostics. You’ll gain insight into the selection of optimal alpha-emitting radionuclides\, the biological advantages of short-range high-energy emissions\, and the complex challenges involved in the development\, production\, and clinical translation of these innovative therapies. Join us to deepen your knowledge and be part of the future of targeted radiopharmaceuticals in oncology. \n\n\n\nOncology \n\n\n\n \n\n\n\nIn this part of the course\, participants will explore the main advantages of alpha-emitting radionuclides in oncology\, while also gaining an understanding of the clinical challenges associated with their use. You will become familiar with the key clinical aspects of Alpha-Therapy\, supported by real-world perspectives and case insights. The course also highlights current and upcoming therapeutic trials\, providing valuable knowledge on the future direction of this rapidly evolving field. \n\n\n\nDosimetry \n\n\n\nParticipants will begin by exploring the basic concepts of dosimetry with alpha emitters\, highlighting key differences from beta emitter dosimetry. The course then delves into the clinical relevance of alpha dosimetry\, demonstrating how accurate dose assessments can inform and optimize the management of patients undergoing treatment with alpha radiotherapeutics. In addition\, the course presents the Alphamet project\, a major European initiative that addresses the specific metrological challenges associated with targeted alpha therapies. By examining the goals and contributions of Alphamet\, learners will gain insight into how this research supports the safe and effective integration of alpha therapy into routine clinical practice. \n\n\n\n \n\n\n\n\n\n\n\nSave yourself a seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now!\n\n\n\n\n\n\n\n\n\n\n\nLearning Objectives\n\n\n\n\n\n\n\nTarget Audience\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTo gain an overview of the main advantages of Alpha-radionuclides\n\n\n\nTo learn about the challenges of alpha emitters\, complex production; transport issues\, waste management and handling\n\n\n\nTo get insights on radiobiology: radiotoxicity & effectiveness\n\n\n\nTo have a comprehensive review of research candidates\n\n\n\nTo provide an overview of the main advantages when using Alpha-Therapy in clinical practice\n\n\n\nTo learn about the clinical challenges when using Alpha-Therapy\n\n\n\nTo get insights into current and future trials focusing on Alpha-Therapy\n\n\n\nTo learn the most basic aspects about dosimetry of alpha emitters showing the main differences with dosimetry of beta emitters\n\n\n\nTo learn how dosimetry results could be used in the management of patients treated with radiopharmaceuticals that include alpha emitters\n\n\n\nTo learn on the Alphamet project\, which addresses the unique and unmet metrological challenges of targeted alpha therapies\, contributing to their safe and optimised implementation into routine clinical practice\n\n\n\n\n\n\n\nNuclear medicine physicians\, radiologists\, medical oncologists\, urologists\, radiation oncologists\, medical physicists\, biologists\, researchers\n\n\n\nRadiochemists\, radiopharmacists\, physicists\, medical physicists\, biologists\n\n\n\n\n\n\n\n\n\n\n\nProgrammeClick to see the full event programme.  View the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n \n\n\n\n \n\n\n\n\n\nDana NiculaeSpeaker \n\n\n\nMarianna TosatoSpeaker \n\n\n\nPablo Mínguez GabiñaSpealer \n\n\n\nAna Denis-BacelarSpeaker \n\n\n\n\n\nEmma AnaheimSpeaker \n\n\n\nWolfgang FendlerSpeaker \n\n\n\nMike SathekgeSpeaker \n\n\n\nJoe O’SullivanSpeaker \n\n\n\n\n\nJanke KleynhansSpeaker \n\n\n\nMathias ZacherlSpeaker \n\n\n\nDaniela Oprea-LagerSpeaker \n\n\n\n\n\n\n\n\n\nRegistration Details\n\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\nEnroll yourselfFind your desired course under ‘Online Courses’  \n\n\n\nEnjoy!Once registered\, you get full access to the course contents on the ESMIT eLearning platform \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/bringing-alpha-therapies-into-clinical-practice/
LOCATION:Online
CATEGORIES:Clinical Nuclear Medicine,Online Course,Radiopharmaceuticals,Self-paced Online Course
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250605T090000
DTEND;TZID=Europe/Vienna:20250606T160000
DTSTAMP:20260421T184442
CREATED:20241017T084223Z
LAST-MODIFIED:20250522T130904Z
UID:1964-1749114000-1749225600@esmit.eanm.org
SUMMARY:GMP for Radiopharmaceuticals
DESCRIPTION:The GMP guidelines provide minimum requirements that a manufacturer of radiopharmaceuticals must meet to assure that their products are consistently high in quality\, from batch to batch\, for clinical use.  \n\n\n\nThe Basics of cGMP is a 2 days on-site ESMIT course\, providing guidance through EU-cGMP regulation for manufacturing\, testing\, and quality assurance of radiopharmaceuticals in order to ensure that a manufactured product is safe for human use. Principles regarding facilities\, equipment qualification\, controlled environmental conditions\, processes and methods validation\, standard operation procedures and user specific requirement\, risk assessment\, and specifications will be detailed. Also\, the main components of investigational new drug and marketing authorisation dossiers will be discussed. \n\n\n\n\n\n\n\nRegister nowThe registration is closed. Please contact us at esmit@eanm.org if you still want to register. \n\n\n\n\n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\nGeneral knowledge regarding GMP and cGMP for Radiopharmaceuticals principles and guidelines. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nRadiopharmacists and radiochemists in translational research\, hospital radiopharmacy and radiopharmaceutical production centres. \n\n\n\n \n\n\n\n\n\n\n\nProgrammeView the Programme\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nDana NiculaeSpeakerBucharest\, Romania \n\n\n\n\n\nPhilip ElsingaSpeakerGroningen\, Netherlands \n\n\n\n\n\nAntero AbrunhosaSpeakerCoimbra\, Portugal \n\n\n\n\n\nRegistration Details\n\n\n\nRegistration FeeMode of PaymentCancellation Policy\n\nCourse Fee               € 950.- \n\n\n\nRegistration Fee includes: \n\n\n\n\nElectronic Course Book\, including all Slides\n\n\n\nCoffee & Lunch Breaks\n\n\n\n\nRegistration Fee does NOT include: \n\n\n\n\nTravel to the Venue\n\n\n\nAccommodation\n\n\n\n\n\n\nRegistration fees need to be paid 1 week prior to the event. In case the payment is not received by this deadline\, the registration needs to be cancelled. Payment can be settled by Credit Card Cheques will not be accepted \n\n\n\n\n\nCancellations must be notified in writing to the EANM Office. Telephone cancellations cannot be accepted. Substitutions will be accepted if the name and e-mail address of the substitute are sent to the EANM Office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course\, we will refund you the fee less a € 100\,- administration charge. After this date\, we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels\, airlines or other means of transportation.
URL:https://esmit.eanm.org/event/gmp-for-radiopharmaceuticals/
LOCATION:Future Health Lab\, Alfred-Adler-Straße 1\, Vienna\, 1100\, Austria
CATEGORIES:Onsite Course,Radiopharmaceuticals
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250613T133000
DTEND;TZID=Europe/Vienna:20250613T143000
DTSTAMP:20260421T184442
CREATED:20241017T081027Z
LAST-MODIFIED:20250605T095541Z
UID:1934-1749821400-1749825000@esmit.eanm.org
SUMMARY:Cardiac Amyloidosis Imaging: Do We Need Quantification?
DESCRIPTION:This webinar provides an overview of the diagnosis of cardiac amyloidosis in nuclear cardiology . Background information on amyloidosis in general is presented and typical disease manifestations are discussed. Furthermore\, the significance of cardiac amyloidosis will be discussed in detail and possible therapeutic options will be explained. In this context\, the relevance of quantification to characterize disease and how to assess reliably the effects of therapy are presented. \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n\nTo gain a insight into the disease of amyloidosis and in particular the cardiac involvement of amyloidosis.\n\n\n\nTo learn the possibilities of quantification of planar and SPECT studies in amyloidosis\n\n\n\n\n \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\n\nNuclear physicians\, cardiologists\, internists and radiologists who are interested in amyloidosis and want to deepen their knowledge of cardiac amyloidosis diagnostics and quantification\n\n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nFederico CaobelliSpeaker \n\n\n\n\n\nIan ArmstrongSpeaker \n\n\n\n\n\nCarmela NappiModerator \n\n\n\n\n\nStephan NekollaModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/cardiac-amyloidosis-imaging-do-we-need-quantification/
CATEGORIES:AI & Quantification,Live Webinars
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20250627T133000
DTEND;TZID=Europe/Vienna:20250627T143000
DTSTAMP:20260421T184442
CREATED:20241017T080743Z
LAST-MODIFIED:20250624T092530Z
UID:1932-1751031000-1751034600@esmit.eanm.org
SUMMARY:Extravascular Administration in Diagnostic and Therapeutic Nuclear Medicine
DESCRIPTION:In nuclear medicine\, diagnostic as well as therapeutic\, radiopharmaceuticals are administered via an intravenous injection\, in a majority of the procedures in a blood vessel at the crook of the arm or on the back of the hand. Occasionally\, the injection fails\, which results in the radiopharmaceutical ending up extravascularly. The consequence of this may be a locally high radiation dose at the injection site\, in some situations high enough to cause severe tissue effects on the patient. Thus\, it is important to recognize the problem and identify the cause in order to decrease the risk. Furthermore\, the management of the situation after such an extravasation must be dealt with thoroughly and this has been the subject of lively debate in recent years. The parameters that have an impact on the radiation dose are among other things\, the physical properties of the radionuclide\, as well as the activity and volume of the radioactive substance retained in the surroundings of the blood vessel. In the case when most of the administered activity ends up extravascular\, the quality of the diagnostic procedure or the effect of the treatment are negatively affected\, which must be addressed. \n\n\n\n \n\n\n\n \n\n\n\n\n\n\n\nRegister nowEnrol in the live webinar now for free! Register now\n\n\n\n\n\n\n\n \n\n\n\n \n\n\n\nLearning Objectives\n\n\n\n \n\n\n\n \n\n\n\nThe aim of this webinar is to highlight the risk and consequences of extravascular administration of radiopharmaceuticals as well as the management of the situation after an extravasation. \n\n\n\n \n\n\n\nTarget Audience\n\n\n\n \n\n\n\nPhysicists\, Physicians\, Technologists\, Nurses \n\n\n\n \n\n\n\n \n\n\n\nFaculty\n\n\n\n \n\n\n\n\n\nSiria MediciSpeaker \n\n\n\n\n\nJochem van der Pol Speaker \n\n\n\n\n\nSigrid Leide SvegbornModerator \n\n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/extravascular-administration-in-diagnostic-and-therapeutic-nuclear-medicine/
CATEGORIES:Instrumentation, Technology, Science,Live Webinars
END:VEVENT
END:VCALENDAR